Plant ID: NPO10856
Plant Latin Name: Passiflora edulis
Taxonomy Genus: Passiflora
Taxonomy Family: Passifloraceae
NCBI TaxonomyDB:
78168
Plant-of-the-World-Online:
321964-2
Stimulant; Tonic
Brazil; Madagascar; Bangladesh; Sudan; Costa Rica; Ethiopia; Rwanda; Peru; Swaziland; Argentina; Bolivia; Cameroon; Malawi; Ecuador; Benin; Cuba; Venezuela; Zambia; United States; Trinidad and Tobago; Zimbabwe; China; Dominican Republic; Paraguay; Gambia; Tanzania; New Caledonia; Mauritius; Morocco; Gabon; Angola; Jamaica; Honduras; Mexico; South Africa; India; Uganda; Mozambique; Colombia; Burundi; Kenya; Fiji
ADORA3; ADORA2A; ADORA1; | |
ACHE; | |
FLT3; CSNK2A1; HASPIN; | |
ADK; HSD17B1; NOX4; | |
CA2; CA12; CA7; CA4; | |
ESR2; | |
MMP12; | |
HIF1A; | |
LMNA; MAPT; THPO; |
Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
---|---|---|---|---|
Cytochrome P450 family 1 | CYP1A2 | Cytochrome P450 1A2 | P05177 | CHEMBL3356 |
Cytochrome P450 family 1 | CYP1B1 | Cytochrome P450 1B1 | Q16678 | CHEMBL4878 |
Cytochrome P450 family 1 | CYP1A1 | Cytochrome P450 1A1 | P04798 | CHEMBL2231 |
Cytochrome P450 family 19 | CYP19A1 | Cytochrome P450 19A1 | P11511 | CHEMBL1978 |
Enzyme_unclassified | ADK | Adenosine kinase | P55263 | CHEMBL3589 |
Enzyme_unclassified | HSD17B1 | Estradiol 17-beta-dehydrogenase 1 | P14061 | CHEMBL3181 |
Enzyme_unclassified | NOX4 | NADPH oxidase 4 | Q9NPH5 | CHEMBL1250375 |
Hydrolase | ACHE | Acetylcholinesterase | P22303 | CHEMBL220 |
Lyase | CA2 | Carbonic anhydrase II | P00918 | CHEMBL205 |
Lyase | CA12 | Carbonic anhydrase XII | O43570 | CHEMBL3242 |
Lyase | CA7 | Carbonic anhydrase VII | P43166 | CHEMBL2326 |
Lyase | CA4 | Carbonic anhydrase IV | P22748 | CHEMBL3729 |
Metallo protease | MMP12 | Matrix metalloproteinase 12 | P39900 | CHEMBL4393 |
Nuclear hormone receptor subfamily 3 group A | ESR2 | Estrogen receptor beta | Q92731 | CHEMBL242 |
Protein Kinase | FLT3 | Tyrosine-protein kinase receptor FLT3 | P36888 | CHEMBL1974 |
Protein Kinase | CSNK2A1 | Casein kinase II alpha | P68400 | CHEMBL3629 |
Protein Kinase | HASPIN | Serine/threonine-protein kinase haspin | Q8TF76 | CHEMBL1075163 |
Small molecule receptor (family A GPCR) | ADORA3 | Adenosine A3 receptor | P0DMS8 | CHEMBL256 |
Small molecule receptor (family A GPCR) | ADORA2A | Adenosine A2a receptor | P29274 | CHEMBL251 |
Small molecule receptor (family A GPCR) | ADORA1 | Adenosine A1 receptor | P30542 | CHEMBL226 |
Transcription Factor | HIF1A | Hypoxia-inducible factor 1 alpha | Q16665 | CHEMBL4261 |
Unclassified | LMNA | Prelamin-A/C | P02545 | CHEMBL1293235 |
Unclassified | MAPT | Microtubule-associated protein tau | P10636 | CHEMBL1293224 |
Unclassified | THPO | Thrombopoietin | P40225 | CHEMBL1293256 |
GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
---|---|---|---|---|---|
MF | GO:0005488; binding | GO:0019825; oxygen binding | 2.244E-09 | 2.699E-05 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, NOX4 |
MF | GO:0003824; catalytic activity | GO:0004089; carbonate dehydratase activity | 2.479E-09 | 2.699E-05 | CA12, CA2, CA4, CA7 |
MF | GO:0003824; catalytic activity | GO:0070330; aromatase activity | 1.597E-08 | 1.159E-04 | CYP19A1, CYP1A1, CYP1A2, CYP1B1 |
MF | GO:0060089; molecular transducer activity | GO:0001609; G-protein coupled adenosine receptor activity | 5.879E-08 | 2.337E-04 | ADORA1, ADORA2A, ADORA3 |
BP | GO:0008152; metabolic process | GO:0006730; one-carbon metabolic process | 1.051E-07 | 2.656E-04 | CA12, CA2, CA4, CA7 |
BP | GO:0009987; cellular process | GO:0001973; adenosine receptor signaling pathway | 1.409E-07 | 2.656E-04 | ADORA1, ADORA2A, ADORA3 |
BP | GO:0008152; metabolic process | GO:0097267; omega-hydroxylase P450 pathway | 2.011E-07 | 3.128E-04 | CYP1A1, CYP1A2, CYP1B1 |
BP | GO:0051179; localization | GO:0015701; bicarbonate transport | 2.407E-07 | 3.241E-04 | CA12, CA2, CA4, CA7 |
MF | GO:0005488; binding | GO:0020037; heme binding | 4.539E-07 | 5.201E-04 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, NOX4 |
BP | GO:0023052; signaling | GO:0032230; positive regulation of synaptic transmission, GABAergic | 4.781E-07 | 5.205E-04 | ADORA2A, CA2, CA7 |
CC | GO:0044464; cell part | GO:0030673; axolemma | 9.338E-07 | 8.841E-04 | ADORA1, ADORA2A, MAPT |
BP | GO:0050896; response to stimulus | GO:0014070; response to organic cyclic compound | 1.668E-06 | 1.453E-03 | ADORA2A, CA2, CSNK2A1, CYP1A1, CYP1A2, CYP1B1, FLT3, NOX4 |
BP | GO:0008152; metabolic process | GO:0019373; epoxygenase P450 pathway | 2.209E-06 | 1.718E-03 | CYP1A1, CYP1A2, CYP1B1 |
BP | GO:0008152; metabolic process | GO:0009404; toxin metabolic process | 2.936E-06 | 2.110E-03 | CYP1A1, CYP1A2, CYP1B1 |
BP | GO:0009987; cellular process | GO:0032849; positive regulation of cellular pH reduction | 4.435E-06 | 2.610E-03 | CA2, CA7 |
CC | GO:0044464; cell part | GO:0099056; integral component of presynaptic membrane | 4.435E-06 | 2.610E-03 | ADORA1, ADORA2A |
MF | GO:0005488; binding | GO:0051879; Hsp90 protein binding | 8.164E-06 | 3.864E-03 | CSNK2A1, HIF1A, MAPT |
BP | GO:0008152; metabolic process | GO:0018894; dibenzo-p-dioxin metabolic process | 8.864E-06 | 4.004E-03 | CYP1A1, CYP1A2 |
BP | GO:0050896; response to stimulus | GO:0001666; response to hypoxia | 1.439E-05 | 5.911E-03 | ADORA1, CYP1A1, HIF1A, LMNA, NOX4 |
Pathway Category Top Level | Pathway Category Second Level | Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
---|---|---|---|---|---|---|
09100 Metabolism | 09103 Lipid metabolism | hsa00140 | Steroid hormone biosynthesis | 7.006E-09 | 2.137E-07 | HSD17B1, CYP1A2, CYP1A1, CYP1B1, CYP19A1 |
09100 Metabolism | 09102 Energy metabolism | hsa00910 | Nitrogen metabolism | 3.755E-09 | 2.137E-07 | CA12, CA2, CA4, CA7 |
09150 Organismal Systems | 09152 Endocrine system | hsa04913 | Ovarian steroidogenesis | 3.539E-07 | 7.196E-06 | HSD17B1, CYP1A1, CYP1B1, CYP19A1 |
09100 Metabolism | 09105 Amino acid metabolism | hsa00380 | Tryptophan metabolism | 1.457E-05 | 2.222E-04 | CYP1A2, CYP1A1, CYP1B1 |
09100 Metabolism | 09111 Xenobiotics biodegradation and metabolism | hsa00980 | Metabolism of xenobiotics by cytochrome P450 | 8.936E-05 | 1.090E-03 | CYP1A2, CYP1A1, CYP1B1 |
09160 Human Diseases | 09161 Cancers | hsa05204 | Chemical carcinogenesis | 1.263E-04 | 1.284E-03 | CYP1A2, CYP1A1, CYP1B1 |
09150 Organismal Systems | 09155 Excretory system | hsa04964 | Proximal tubule bicarbonate reclamation | 3.438E-04 | 2.996E-03 | CA2, CA4 |
ICD10 Disease Category | Disease Name | ICD10 Code | Associated Disease Targets (Association Ref: TTD database) |
---|---|---|---|
C00-D49: Neoplasms | Lymphoma | C81-C86 | HIF1A; |
L00-L99: Diseases of the skin and subcutaneous tissue | Psoriasis | L40 | FLT3; |
J00-J99: Diseases of the respiratory system | Asthma | J45 | MMP12; ADORA1; ADORA2A; |
I00-I99: Diseases of the circulatory system | Heart failure | I50 | ADORA1; |
A00-B99: Certain infectious and parasitic diseases | Pediculus humanus capitis | B85.0 | ACHE; |
C00-D49: Neoplasms | Solid tumours | C00-D48 | FLT3; HIF1A; |
I00-I99: Diseases of the circulatory system | Ischemia | I99.8 | ADORA3; |
C00-D49: Neoplasms | Acute myeloid leukemia | C92.0 | FLT3; |
C00-D49: Neoplasms | Myelofibrosis | C94.4, D47.4 | FLT3; |
E00-E89: Endocrine, nutritional and metabolic diseases | Inflammation | E08-E13, E10.2, E11, E11.2, E13.2, I73.9, I80-I82, N00-N29, G89 | ADORA3; |
H00-H59: Diseases of the eye and adnexa | Glaucoma | H40-H42 | ACHE; ADORA1; ADORA2A; ADORA3; |
NA: NA | GIST | NA | FLT3; |
C00-D49: Neoplasms | Myeloid leukemia | C92 | FLT3; |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Mild cognitive impairment | F06.7 | ACHE; |
N00-N99: Diseases of the genitourinary system | Prostate disease | N42.9 | CYP19A1; |
C00-D49: Neoplasms | Prostate cancer | C61 | FLT3; |
I00-I99: Diseases of the circulatory system | Arteriosclerosis | I70 | ADORA2A; |
I00-I99: Diseases of the circulatory system | Atherosclerosis | I70 | MMP12; |
G00-G99: Diseases of the nervous system G00-G99 | Neuropathic pain | G64, G90.0 | ADORA1; ADORA2A; |
G00-G99: Diseases of the nervous system G00-G99 | Neurodegenerative disease | G30-G32 | ACHE; MAPT; |
I00-I99: Diseases of the circulatory system | Hypertension | I10-I16 | ADORA1; ADORA2A; |
I00-I99: Diseases of the circulatory system | Cerebrovascular ischaemia | I61-I63 | ADORA3; |
G00-G99: Diseases of the nervous system G00-G99 | Central nervous system disease | G00-G99 | MAPT; |
N00-N99: Diseases of the genitourinary system | Urinary dysfunction | N39.3-N39.4 | ACHE; |
NA: NA | Upper abdominal bloating | NA | ACHE; |
G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis | G70.0 | ACHE; |
G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis diagnosis | G70.0 | ACHE; |
J00-J99: Diseases of the respiratory system | Chronic obstructive pulmonary disease | J40-J44, J47 | MMP12; ADORA2A; |
H00-H59: Diseases of the eye and adnexa | Chronic glaucoma | H40-H42 | ACHE; |
I00-I99: Diseases of the circulatory system | Aortic aneurysm | I71 | MMP12; |
C00-D49: Neoplasms | Leukemia | C90-C95 | FLT3; |
K00-K95: Diseases of the digestive system | Duodenal ulcers | K25-K27 | CA2; |
NA: NA | Anaplastic mixed oligoastrocytoma | NA | FLT3; |
H00-H59: Diseases of the eye and adnexa | Open-angle glaucoma | H40-H42 | CA4; ACHE; CA2; |
H00-H59: Diseases of the eye and adnexa | Ocular hypertension | H40.0 | CA4; |
N00-N99: Diseases of the genitourinary system | Renal failure | N17, N18, N19 | ADORA1; |
I00-I99: Diseases of the circulatory system | Orthostatic hypotension | I95.1 | ADORA1; |
C00-D49: Neoplasms | CLL | NA | FLT3; |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cognitive disorders | F01-F07, F04, F05, R41.3 | ACHE; ADORA1; MAPT; |
S00-T88: Injury, poisoning and certain other consequences of external causes | Allergy | T78.4 | ADORA1; |
G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | ACHE; MAPT; |
J00-J99: Diseases of the respiratory system | Allergic rhinitis | J00, J30, J31.0, T78.4 | ADORA2A; |
K00-K95: Diseases of the digestive system | Xerostomia | K11.7, R68.2 | ACHE; |
C00-D49: Neoplasms | Bladder cancer | C67 | CYP19A1; |
J00-J99: Diseases of the respiratory system | Airway inflammation | J00-J99 | FLT3; |
G00-G99: Diseases of the nervous system G00-G99 | Parkinson's disease | G20 | ACHE; ADORA1; ADORA2A; |
G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | ACHE; ADORA2A; ADK; |
C00-D49: Neoplasms | Breast cancer | C50 | FLT3; CYP19A1; |
C00-D49: Neoplasms | Pancreatic cancer | C25 | FLT3; |
C00-D49: Neoplasms | AML | NA | FLT3; |
C00-D49: Neoplasms | Cancer | C00-C96 | CSNK2A1; FLT3; ACHE; HIF1A; ADORA3; |
C00-D49: Neoplasms | Advanced breast cancer | C50 | CYP19A1; |
A00-B99: Certain infectious and parasitic diseases | Malaria | B54 | ADORA3; |
C00-D49: Neoplasms | Glioblastoma | NA | FLT3; |
S00-T88: Injury, poisoning and certain other consequences of external causes | Poisoning due to pesticides and chemicals | T36-T50 | ACHE; |
L00-L99: Diseases of the skin and subcutaneous tissue | Diabetic foot ulcer | L88-L89 | ADORA2A; |
I00-I99: Diseases of the circulatory system | Cardiac disease | I00-I99 | ADORA1; |
I00-I99: Diseases of the circulatory system | Cardiac arrhythmias | I47-I49 | ADORA1; |
I00-I99: Diseases of the circulatory system | Pulmonary arterial hypertension | I27.0, I27.2 | HIF1A; |
C00-D49: Neoplasms | Acute lymphoblastic leukemia | C91.0 | FLT3; |
I00-I99: Diseases of the circulatory system | Edema associated with congestive heart failure | I50, R60.9 | CA2; |
C00-D49: Neoplasms | Inflammatory disease | C11, C44, K75.9, M00-M25 | MMP12; |
NA: NA | Early satiation associated with functional dyspepsia | NA | ACHE; |
C00-D49: Neoplasms | Gliosarcoma | NA | FLT3; |
G00-G99: Diseases of the nervous system G00-G99 | Multiple scierosis | G35 | ADORA1; |
G00-G99: Diseases of the nervous system G00-G99 | Epileptic seizures | G40, P90, R56 | ACHE; ADK; |
G00-G99: Diseases of the nervous system G00-G99 | Epilepsy | G40 | ADK; |
I00-I99: Diseases of the circulatory system | Acute and chronic heart failure | I50 | ADORA1; |
S00-T88: Injury, poisoning and certain other consequences of external causes | Poison intoxication | T36-T50 | ACHE; |
I00-I99: Diseases of the circulatory system | High blood pressure | I10-I16 | CA2; |
E00-E89: Endocrine, nutritional and metabolic diseases | Diabetes | E23.2, N25.1 | ADORA1; |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Anxiety disorder | F32, F40-F42 | ACHE; |
C00-D49: Neoplasms | Colorectal cancer | C18-C21 | FLT3; |
C00-D49: Neoplasms | Colon cancer | C50 | FLT3; |
E00-E89: Endocrine, nutritional and metabolic diseases | Hyperlipidaemia | E78 | ADORA1; |
E00-E89: Endocrine, nutritional and metabolic diseases | Hypertriglyceridemia | E78.1, E78.2, E78.3, I47-I49 | ADORA1; |
R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Fatigue | R53 | ADORA1; |
I00-I99: Diseases of the circulatory system | Coronary disorder diagnosis | I20-I25 | ADORA2A; |
R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Convulsions | R56.0 | ADK; |
W85-W99: Exposure to electric current, radiation and extreme ambient air temperature and pressure | Radionuclide imaging | W88 | ADORA2A; |
C00-D49: Neoplasms | Hepatocellular carcinoma | C22.0 | ADORA3; |
NA: NA | Hematopoietic stem cell transplantation | NA | FLT3; |
NA: NA | Hepatitis C virus infection | NA | ADORA3; |
A00-B99: Certain infectious and parasitic diseases | Helminth infection | A00-B99 | ACHE; |
NA: NA | Edema | NA | CA2; |
N00-N99: Diseases of the genitourinary system | Endometriosis | N80 | CYP19A1; |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Insomnia | F51.0, G47.0 | CA2; |
C00-D49: Neoplasms | Hormonally-responsive breast cancer | C50 | CYP19A1; |
E00-E89: Endocrine, nutritional and metabolic diseases | Atrial fibrillation | E78, I48 | ADORA1; |
E00-E89: Endocrine, nutritional and metabolic diseases | Autoimmune diabetes | E08-E13 | ADORA1; |
A00-B99: Certain infectious and parasitic diseases | Sepsis | A40, A41 | ADORA1; |
A00-B99: Certain infectious and parasitic diseases | Human immunodeficiency virus infection | B20-B26 | FLT3; |